TRT Monitoring: The Follow-Up Men Skip
Starting testosterone is not the finish line. The follow-up is where responsible care separates itself from casual prescribing.
TRT gets marketed like a switch: low energy in, testosterone out, problem solved. Real care is not that simple. Testosterone therapy can be helpful for the right man, with the right diagnosis, at the right dose, and with the right monitoring. But when follow-up gets skipped, men lose the part of care that keeps treatment useful, measurable, and safer.
The goal is not just to raise a number. The goal is to improve symptoms while watching the markers that tell us whether the plan still makes sense.
Why follow-up matters
The Endocrine Society guideline highlights the importance of an appropriate diagnostic workup and monitoring plan. After treatment starts, clinicians should assess whether the patient is responding, whether side effects are emerging, and whether the treatment regimen is being followed correctly.
That sounds basic, but it is exactly where many men fall through the cracks. They start therapy, feel a little better, then stop tracking. Or they chase higher numbers without asking whether sleep, blood pressure, mood, libido, recovery, fertility goals, and cardiovascular risk are being watched.
Hematocrit: the lab men should not ignore
Testosterone therapy can increase red blood cell concentration in some men. That is why CBC and hematocrit matter before and during treatment. Hematocrit is not glamorous, but it is one of the key safety markers that helps determine whether the dose, frequency, route, or overall plan needs adjustment.
If a man is feeling better but hematocrit is climbing, that is not a detail to brush off. It is a signal to pause, review the plan, and manage risk.
Blood pressure belongs in the TRT conversation
Blood pressure is one of the easiest numbers to check and one of the easiest to ignore. That is a mistake. Men considering or using TRT are often already dealing with midlife risk factors: weight gain, sleep apnea risk, alcohol creep, stress, insulin resistance, or family history.
Monitoring blood pressure gives the follow-up visit a broader view. If energy improves but blood pressure worsens, the plan still needs attention. TRT care should not tunnel-vision on testosterone while missing cardiovascular basics.
Does Testosterone Therapy Cause Prostate Cancer? What the Latest Research Says
For decades, testosterone replacement therapy (TRT) has carried a cloud of suspicion when it comes to prostate cancer. The concern dates back to the mid-20th century, when Nobel Prize-winning research showed that removing testosterone could shrink advanced prostate tumors. The logic seemed straightforward: if cutting testosterone fights prostate cancer, then adding testosterone must fuel it. But modern research tells a very different story. Three large-scale studies — spanning tens of thousands of men and multiple countries — have now examined this question rigorously, and the results are remarkably consistent.
Fortunately, newer research has been reassuring. A large systematic review and meta-analysis combined data from 41 randomized controlled trials involving more than 11,000 men and found no significant increase in prostate cancer among men receiving testosterone therapy compared with placebo. The same was true when researchers looked specifically at clinically significant prostate cancers, those most likely to affect health and require treatment. While testosterone therapy is not appropriate for every man and prostate health should still be monitored, current evidence does not support the long-held belief that appropriately prescribed testosterone therapy increases the risk of developing prostate cancer.
For the average man with low testosterone and no red flags on prostate screening, however, the fear that TRT will cause prostate cancer is not supported by the current evidence.
PSA monitoring should be individualized based on age, history, risk, symptoms, and shared decision-making. The Endocrine Society recommends discussing prostate cancer risk and monitoring for appropriate men before treatment, and reassessing risk after therapy starts. It also recommends urologic consultation for certain PSA rises or concerning prostate findings during the first year of treatment.
That does not mean TRT causes prostate cancer. It means prostate-related risk deserves a clear conversation before and during treatment, especially in men with higher baseline risk or concerning changes.
Lipids and metabolic health show the bigger picture
TRT patients are not lab values floating in space. They are whole people with sleep habits, waist circumference, blood pressure, glucose control, cholesterol patterns, training routines, and stress loads. Lipids, fasting glucose, A1c, and weight or waist trends help show whether the man is actually getting healthier.
For many men, the best TRT outcomes come when treatment is paired with better sleep, strength training, protein intake, and cardiometabolic risk reduction. Follow-up should make that visible.
Symptoms matter as much as numbers
A testosterone level can move without a man meaningfully improving. That is why symptom tracking matters. Energy, libido, erections, mood, focus, sleep quality, workout recovery, irritability, acne, fluid retention, and fertility goals all belong in the follow-up conversation.
Good TRT care asks: What improved? What did not? What got worse? Are we treating the original problem, or are we just chasing a lab number?
What a responsible follow-up should include
- Symptom response: energy, libido, erections, mood, focus, sleep, and recovery.
- Testosterone levels: interpreted according to timing, formulation, dose, and clinical response.
- CBC and hematocrit: to watch red blood cell response.
- Blood pressure: because cardiovascular basics still matter.
- PSA discussion: when appropriate based on age, risk, history, and shared decision-making.
- Lipids and metabolic markers: to understand the broader health trajectory.
- Side effects and fertility goals: because TRT can affect sperm production and is not neutral for men trying to preserve fertility.
The bottom line
TRT should not be casual. If a man is going to start therapy, he deserves follow-up that is structured, honest, and specific. The right question is not only, “Did the testosterone go up?” The better question is, “Is this man healthier, safer, and actually better?”
That is what monitoring is for.
Back to the TRT playbookSources
- Endocrine Society: Testosterone Therapy in Men With Hypogonadism guideline.
